FindTrial
Sign In

Outcomes of intravitreal aflibercept (Eylea®) treatment for treatment-naïve contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed with intravitreal ranibizumab in the first eye

Outcomes of intravitreal aflibercept (Eylea®) treatment for treatment-naïve contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed with intravitreal ranibizumab in the first eye

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0002448
Enrollment
21
Registered
2017-09-05
Start date
2013-11-05
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The second-affected eyes in these patients will be prospectively treated with 2.0 mg intravitreal aflibercept. After three loading doses of aflibercept (at months 0, 1, and 2), the second-affe

Sponsors

Seoul National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who developed new-onset nAMD in a second-affected eye, who had previously shown a poor response to as-needed ranibizumab in their first-affected eyes. Patients were diagnosed with nAMD when there was evidence of choroidal neovascularization (CNV) associated with nondrusenoid retinal pigment epithelium detachment (PED), serous or hemorrhagic retinal detachment, subretinal hemorrhage, subretinal pigment epithelial hemorrhage, or subretinal fibrosis.

Exclusion criteria

Exclusion criteria: (1) patients with diabetic retinopathy or retinal vein occlusion, (2) patients with coexisting epiretinal membranes or vitreomacular traction syndrome, (3) patients with neovascularized maculopathies other than AMD, such as pathological myopia, angioid streaks, and (4) patients with a history of prior photocoagulation, intravitreal anti-VEGF injection, photodynamic therapy, intravitreal or sub-tenon steroid injection, vitrectomy surgery, or intravitreal gas injection.

Design outcomes

Primary

MeasureTime frame
visual acuity (VA) in the second-affected eyes;central macular thickness (CMT) in the second-affected eyes;rate of subretinal fluid (SRF) in the second-affected eyes ; rate of intraretinal fluid (IRF) in the second-affected eyes;rate of serosanguineous PED in the second-affected eyes—

Secondary

MeasureTime frame
Comparison of VA, CMT and retinal morphlogy between the first and the second eyes;Comparison of CMT between the first and the second eyes;Comparison of SRF rate between the first and the second eyes;Comparison of IRF rate between the first and the second eyes;Comparison of PED rate between the first and the second eyes—

Countries

Korea, Republic of

Contacts

Public ContactDae Joong Ma

Seoul National University Hospital

daejoongma@gmail.com+82-2-2072-3110

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026